77 related articles for article (PubMed ID: 23630217)
1. Insights from mixture cure modeling of molecular markers for prognosis in breast cancer.
Yilmaz YE; Lawless JF; Andrulis IL; Bull SB
J Clin Oncol; 2013 Jun; 31(16):2047-54. PubMed ID: 23630217
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of and therapeutic options for contralateral axillary lymph node metastasis in breast cancer.
Morcos B; Jaradat I; El-Ghanem M
Eur J Surg Oncol; 2011 May; 37(5):418-21. PubMed ID: 21316187
[TBL] [Abstract][Full Text] [Related]
3. Locoregional recurrence in patients with triple-negative breast cancer: preliminary results of a single institution study.
Dragun AE; Pan J; Rai SN; Kruse B; Jain D
Am J Clin Oncol; 2011 Jun; 34(3):231-7. PubMed ID: 20805742
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
[TBL] [Abstract][Full Text] [Related]
5. Predicting axillary sentinel node status in patients with primary breast cancer.
Kolarik D; Pecha V; Skovajsova M; Zahumensky J; Trnkova M; Petruzelka L; Halaska M; Sottner O; Otcenasek M; Kolarova H
Neoplasma; 2013; 60(3):334-42. PubMed ID: 23374005
[TBL] [Abstract][Full Text] [Related]
6. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
[TBL] [Abstract][Full Text] [Related]
7. Clinical features and survival analysis of T1mic, a, bN0M0 breast cancer.
Li J; Liu X; Tong Z
Jpn J Clin Oncol; 2012 Jun; 42(6):471-6. PubMed ID: 22493058
[TBL] [Abstract][Full Text] [Related]
8. [Prognosis prediction of S-phase fraction and p53, c-erbB-2, estrogen receptor, progesterone receptor in axillary node-negative breast cancer].
Zhang S; Yuan Y; Wang X
Zhonghua Wai Ke Za Zhi; 1997 Aug; 35(8):475-7. PubMed ID: 10678068
[TBL] [Abstract][Full Text] [Related]
9. Molecular class as a predictor of locoregional and distant recurrence in the neoadjuvant setting for breast cancer.
Vargo JA; Beriwal S; Ahrendt GM; Soran A; Johnson RR; McGuire K; Bhargava R
Oncology; 2011; 80(5-6):341-9. PubMed ID: 21791944
[TBL] [Abstract][Full Text] [Related]
10. Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers.
Nofech-Mozes S; Trudeau M; Kahn HK; Dent R; Rawlinson E; Sun P; Narod SA; Hanna WM
Breast Cancer Res Treat; 2009 Nov; 118(1):131-7. PubMed ID: 19189211
[TBL] [Abstract][Full Text] [Related]
11. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel.
Millar EK; Graham PH; O'Toole SA; McNeil CM; Browne L; Morey AL; Eggleton S; Beretov J; Theocharous C; Capp A; Nasser E; Kearsley JH; Delaney G; Papadatos G; Fox C; Sutherland RL
J Clin Oncol; 2009 Oct; 27(28):4701-8. PubMed ID: 19720911
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up results of breast cancer patients with sentinel lymph node biopsy using periareolar injection.
Imasato M; Shimazu K; Tamaki Y; Taguchi T; Tanji Y; Kim SJ; Noguchi S
Am J Surg; 2010 Apr; 199(4):442-6. PubMed ID: 19596117
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
14. Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma.
Liu F; Cui L; Zhang Y; Chen L; Wang Y; Fan Y; Lei T; Gu F; Lang R; Pringle GA; Zhang X; Chen Z; Fu L
Breast Cancer Res Treat; 2010 Dec; 124(3):677-88. PubMed ID: 20213083
[TBL] [Abstract][Full Text] [Related]
15. The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer.
Gabos Z; Thoms J; Ghosh S; Hanson J; Deschênes J; Sabri S; Abdulkarim B
Breast Cancer Res Treat; 2010 Nov; 124(1):187-94. PubMed ID: 20814819
[TBL] [Abstract][Full Text] [Related]
16. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
[TBL] [Abstract][Full Text] [Related]
17. Does the metastatic lymph node ratio influence the disease-free survival of patients with breast cancer: single-center experiences.
Oven Ustaalioglu BB; Bilici A; Kefeli U; Seker M; Yildirim E; Salepci T; Oncel M; Kement M; Gumus M
Oncology; 2010; 79(1-2):105-11. PubMed ID: 21088436
[TBL] [Abstract][Full Text] [Related]
18. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
Partin JF; Mamounas EP
Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and predictive factors in early-stage breast cancer.
Cianfrocca M; Goldstein LJ
Oncologist; 2004; 9(6):606-16. PubMed ID: 15561805
[TBL] [Abstract][Full Text] [Related]
20. Patients with recurrent breast cancer: does the primary axillary lymph node status predict more aggressive tumor progression?
Rack B; Janni W; Gerber B; Strobl B; Schindlbeck C; Klanner E; Rammel G; Sommer H; Dimpfl T; Friese K
Breast Cancer Res Treat; 2003 Nov; 82(2):83-92. PubMed ID: 14692652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
